Healon PRO Sodium Hyaluronate Ophthalmic Viscoelastic Device (OVD); Healon Duet PRO II Dual Pack Sodium Hyaluronate Opht
Johnson & Johnson Surgical Vision, Inc. · Decision date Dec 16, 2025
What did the FDA decide?
FDA records P810031/S081 as a supplement to PMA P810031, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Dec 16, 2025.
FDA approval order statement
the addition of an alternative supplier of the holder assembly used to deliver the subject ophthalmic viscosurgical devices during surgery
- Regulatory pathway
- PMA supplement
- Supplement type
- 30-Day Notice
- Clinical specialty
- Ophthalmic
- Decision date
- Dec 16, 2025
- FDA change category
- Process Change - Manufacturer/Sterilizer/Packager/Supplier
Regulatory record facts
- Identifier
- P810031/S081
- Regulatory pathway
- PMA supplement
- Product code
- LZP
- Decision code
- OK30
- Decision date
- Dec 16, 2025
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: AID, SURGICAL, VISCOELASTIC.
- Product code
- LZP
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P810031. Subsequent supplements may change the device or its indications.
FDA decision timeline
P810031 · Original PMA
HEALON, HEALON GV, HEALON5 PRODUCTS SODIUM HYALURONATE OPHTHALMIC VISCOELASTIC DEVICES
P810031/S080 · Related supplement
Healon EndoCoat PRO Sodium Hyaluronate Ophthalmic Viscoelastic Device (OVD), Healon Duet PRO II Dual Pack Sodium Hya
P810031/S081 received
Application receipt date recorded by FDA.
P810031/S081 · FDA decision
30-Day Notice
P810031/S082 · Related supplement
Healon PRO, Healon GV PRO and Healon5 PRO Ophthalmic Viscosurgical Devices (OVD)
P810031/S083 · Related supplement
Healon EndoCoat PRO Sodium Hyaluronate Ophthalmic Viscoelastic Device (OVD); Healon Duet PRO II Dual Pack Sodium Hya
Timeline entries are records held by MedtechLedger for P810031. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P810031
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | PMA approval | Jan 14, 1983 | FDA | |
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 28, 2025 | FDA | |
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Jul 28, 2026 | FDA | |
| Johnson & Johnson Surgical Vision, Inc. | PMA supplement | Oct 30, 2026 | FDA |
Explore the linked device profile
Other records with product code LZP
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Alcon Laboratories | PMA supplement | Oct 1, 2026 | FDA | |
PROVISC Ophthalmic Viscosurgical DeviceP890047/S072 | Alcon Research, Ltd. | PMA supplement | Oct 1, 2026 | FDA |
Ophthalmic Viscosurgical Device FamilyP000046/S032 | Anika Therapeutics, Inc. | PMA supplement | Aug 28, 2026 | FDA |
| Alcon Laboratories | PMA supplement | Aug 4, 2026 | FDA | |
PROVISC Ophthalmic Viscosurgical DeviceP890047/S070 | Alcon Research, Ltd. | PMA supplement | Aug 4, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Johnson & Johnson Surgical Vision, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 31 Technology Dr., Suite 200, Irvine, CA, 92618
Sources and methodology
- Original FDA record: P810031/S081
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records



